Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
1 recherche sur le mot-clé 'Research Units on Pediatric Psychopharmacology (RUPP)'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials / Lawrence SCAHILL in Journal of Autism and Developmental Disorders, 43-3 (March 2013)
[article]
Titre : Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials Type de document : Texte imprimé et/ou numérique Auteurs : Lawrence SCAHILL, Auteur ; Victoria HALLETT, Auteur ; Michael G. AMAN, Auteur ; Christopher J. MCDOUGLE, Auteur ; L. Eugene ARNOLD, Auteur ; James T. MCCRACKEN, Auteur ; Elaine TIERNEY, Auteur ; Yanhong DENG, Auteur ; James DZIURA, Auteur ; Benedetto VITIELLO, Auteur Article en page(s) : p.739-746 Langues : Anglais (eng) Mots-clés : Social disability Autism Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Social withdrawal Risperidone Aberrant Behavior Checklist Index. décimale : PER Périodiques Résumé : There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials. We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded, multi-site, randomized trials with risperidone. Study 1 included 52 subjects assigned to placebo and 49 subjects to risperidone under double-blind conditions. Study 2 included 49 subjects assigned to risperidone only and 75 subjects assigned to risperidone plus parent training. After 8 weeks of treatment, all active treatments were superior to placebo (effect sizes ranging from 0.42 to 0.65). The findings suggest that the Social Withdrawal subscale may be a useful measure of social disability in acute treatment trials. En ligne : http://dx.doi.org/10.1007/s10803-012-1689-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=192
in Journal of Autism and Developmental Disorders > 43-3 (March 2013) . - p.739-746[article] Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials [Texte imprimé et/ou numérique] / Lawrence SCAHILL, Auteur ; Victoria HALLETT, Auteur ; Michael G. AMAN, Auteur ; Christopher J. MCDOUGLE, Auteur ; L. Eugene ARNOLD, Auteur ; James T. MCCRACKEN, Auteur ; Elaine TIERNEY, Auteur ; Yanhong DENG, Auteur ; James DZIURA, Auteur ; Benedetto VITIELLO, Auteur . - p.739-746.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 43-3 (March 2013) . - p.739-746
Mots-clés : Social disability Autism Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Social withdrawal Risperidone Aberrant Behavior Checklist Index. décimale : PER Périodiques Résumé : There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials. We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded, multi-site, randomized trials with risperidone. Study 1 included 52 subjects assigned to placebo and 49 subjects to risperidone under double-blind conditions. Study 2 included 49 subjects assigned to risperidone only and 75 subjects assigned to risperidone plus parent training. After 8 weeks of treatment, all active treatments were superior to placebo (effect sizes ranging from 0.42 to 0.65). The findings suggest that the Social Withdrawal subscale may be a useful measure of social disability in acute treatment trials. En ligne : http://dx.doi.org/10.1007/s10803-012-1689-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=192